左炔诺孕酮宫内缓释系统对子宫腺肌病患者月经模式的影响  

Effects of Levonorgestrel-Releasing Intrauterine System on Menstrual Patterns of Patients with Adenomyosis

作　　者：段志珍[1] 洪莉[1] 程艳香[1] 

机构地区：[1]武汉大学人民医院妇产科,430060

出　　处：《医药导报》2013年第1期34-36,共3页Herald of Medicine

基　　金：湖北省人口与计划生育委员会基金资助项目(JS-2010016)

摘　　要：目的探讨左炔诺孕酮宫内缓释系统对子宫腺肌病患者月经模式的影响。方法选择因子宫腺肌病放置左炔诺孕酮宫内缓释系统的患者70例。采用月经失血法、痛经评分法评价患者放置前,放置后1,3,6,9个月月经模式。结果 65例患者完成随访,随访率为92.9%。月经量评分:放置前(193.03±134.79)分,放置后1个月(21.08±32.13)分,放置后3个月(5.56±7.16)分,放置后6个月(2.13±4.28)分,放置后9个月(1.51±2.89)分,与放置前比较,放置后1,3,6,9个月患者,月经量、血块均明显减少;其中27例痛经患者痛经评分:放置前(1.85±0.82)分,放置后1个月(0.48±0.51)分,放置后3个月(0.13±0.34)分,放置后6个月为0分,上环后痛经明显缓解。结论左炔诺孕酮宫内缓释系统可改善子宫腺肌病患者月经情况。Objective To explore the variation of menstrual patterns of patients who suffered from adenomyosis after the treatment with levonnrgestrel via intrauterine releasing system. Methods Seventy patients with adenomyosis who were inserted with levonorgestrel-releasing intrauterine system were selected. The variation of menstrual patterns was assessed through menstrual blood loss method and dysmenorrhea scoring at beginning and 1, 3, 6, 9 months after insertion. Results Sixty-five patients completed fnllow-up, which accounted for 92.9%. Menstrual blood w）lume of baseline and 1,3,6,9 months after therapy was （ 193.03±134.79 ） , （21.08±32.13） , （5.56±7.16）, （ 2.13±4.28 ） , （1.51±2.89） , respectively. Compared to the baseline, the menstrual blood volume and blood clot of the patients were significantly decreased at 1,3,6,9 months after treatment. The dysmenorrhea score of 27 patients at the same time point was 1.85-＋0.82 （prior-insertion）, 0.48 ＋0.51 （one month post- insertion）, 0. 13＋-0.34 （three months post-insertion）, 0 （six months post-insertion）, respectively, and the dysmenorrheal normally occurred after vaginal ring operation was obviously relieved after insertion. Conclusion Levonorgestrel-releasing intrauterine system displays good therapeutic effect on improving the menstrual patterns nf patients with adenomyosis.

关 键 词：左炔诺孕酮宫内缓释系统 子宫腺肌病 月经模式 

分 类 号：R979.2[医药卫生—药品] R453[医药卫生—药学]